Carvedilol vs Diltiazem: side effects in FDA adverse event reports
At a glance
| Carvedilol | Diltiazem | |
|---|---|---|
| Drug class | alpha-Adrenergic Blocker, beta-Adrenergic Blocker | – |
| Brand names | – | Diltiazem Hydrochloride |
| FAERS reports | 134,417 | 34,205 |
| Serious | 70% | 74% |
| Death outcome | 16,351 | 5,131 |
| Boxed warning | No | No |
Signals both drugs share
No strong shared signal after removing coding and lab terms.
Labeled signals distinctive to Carvedilol
- Cardiac failure congestive — n=4,455, PRR 9.0 Labeled (related wording)
- Renal failure chronic — n=356, PRR 7.4 Labeled (related wording)
- Cardiac failure chronic — n=338, PRR 13.4 Labeled (related wording)
- Bundle branch block left — n=260, PRR 10.1 Labeled (related wording)
- Ventricular hypokinesia — n=211, PRR 10.9 Labeled (related wording)
Labeled signals distinctive to Diltiazem
- None stood out among the strongest labeled signals.
Common questions
Which has more reported side effects, Carvedilol or Diltiazem?
Carvedilol has 134,417 FAERS reports and Diltiazem 34,205. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (70% vs 74%) is a better like-for-like signal of the kind of problems reported.
Which side effects do Carvedilol and Diltiazem share?
They share no strong flagged signal after artifacts and lab terms are removed.
Is Carvedilol or Diltiazem safer?
FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.
Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.